Skip to content

Study · Randomized controlled trial · n = 20 · 2018

9 results

Effects of Teriparatide and Vibration on Bone Mass and Bone Strength in People with Bone Loss and Spinal Cord Injury: A Randomized, Controlled Trial.

Edwards WB, Simonian N, Haider IT, Anschel AS, Chen D, Gordon KE, Gregory EK, Kim KH, Parachuri R, Troy KL, Schnitzer TJ

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research28 Jun 2018Cited by 57 (Europe PMC)

PMID29905973 (opens in a new tab)DOI10.1002/jbmr.3525 (opens in a new tab)PepBankPUB-29905973
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with chronic spinal cord injury, teriparatide with sham vibration significantly increased spine aBMD from baseline at 12 months.

    In plain wordsIn people with spinal cord injury, teriparatide with sham vibration increased spine bone density from baseline at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine aBMD at 12 months
    Study

    n = 20

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · 12 monthsAs given in this study (human).

    Measurements

    Spine aBMD increase from baseline
    4.8 to 5.5%
    both teriparatide groups at 12 months

    Source sentences

    Summary
    At the end of the initial 12 months, both groups treated with teriparatide demonstrated a significant increase in areal bone mineral density (aBMD) at the spine (4.8% to 5.5%).
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

Studies that did not test the peptide alone8

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In chronic spinal cord injury, knee cortical bone increased in all groups, without a difference in response magnitude between treatments.

    In plain wordsIn people with spinal cord injury, knee cortical bone increased similarly across teriparatide and placebo regimens.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeKnee cortical bone response between groups
    Study

    n = 61

    Comparator
    Placebo plus vibration
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Knee cortical bone increase
    2.2 to 4.2%
    all groups after 12 months

    Source sentences

    Summary
    A small but significant increase (2.2% to 4.2%) in computed tomography measurements of cortical bone at the knee was observed in all groups after 12 months; however, the magnitude of response was not different amongst treatment groups and improvements to finite element-predicted bone strength were not observed.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In chronic spinal cord injury, no improvement in finite element-predicted bone strength was observed across study groups.

    In plain wordsIn people with spinal cord injury, predicted bone strength did not improve across teriparatide and placebo regimens.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeFinite element-predicted bone strength
    Study

    n = 61

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    A small but significant increase (2.2% to 4.2%) in computed tomography measurements of cortical bone at the knee was observed in all groups after 12 months; however, the magnitude of response was not different amongst treatment groups and improvements to finite element-predicted bone strength were not observed.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In people with chronic spinal cord injury, teriparatide plus active vibration significantly increased spine aBMD from baseline at 12 months.

    In plain wordsIn people with spinal cord injury, teriparatide plus active vibration increased spine bone density from baseline at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine aBMD at 12 months with active vibration
    Study

    n = 21

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Spine aBMD increase from baseline
    4.8 to 5.5%
    both teriparatide groups at 12 months

    Source sentences

    Summary
    At the end of the initial 12 months, both groups treated with teriparatide demonstrated a significant increase in areal bone mineral density (aBMD) at the spine (4.8% to 5.5%).
    1 context sentence
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism

    In chronic spinal cord injury, teriparatide regimens produced a marked bone metabolism marker response, with direction unspecified.

    In plain wordsIn people with spinal cord injury, teriparatide regimens produced a marked response in blood markers of bone metabolism.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedBone metabolism marker response
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The increase in spine aBMD was consistent with a marked response in serum markers of bone metabolism (ie, CTX, P1NP, BSAP), but no treatment effect was observed at the hip.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In chronic spinal cord injury, teriparatide regimens showed no treatment effect on hip aBMD during the initial study.

    In plain wordsIn people with spinal cord injury, teriparatide regimens showed no hip bone density benefit versus placebo with vibration.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeHip aBMD treatment effect
    Study

    n: not reported in source

    Comparator
    Placebo plus vibration
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The increase in spine aBMD was consistent with a marked response in serum markers of bone metabolism (ie, CTX, P1NP, BSAP), but no treatment effect was observed at the hip.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 07HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In chronic spinal cord injury, the teriparatide extension with optional vibration further increased spine aBMD, especially after initial teriparatide assignment.

    In plain wordsIn people with spinal cord injury, spine bone density increased further during the teriparatide extension with optional vibration.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine aBMD after extension
    Study

    n = 25

    Comparator
    Original baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Total spine aBMD increase
    7.1 to 14.4%
    from original baseline after extension

    Source sentences

    Summary
    Teriparatide treatment after the 12-month extension resulted in further increases to spine aBMD (total increase from baseline 7.1% to 14.4%), which was greater in patients initially randomized to teriparatide.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 08HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In chronic spinal cord injury, knee cortical bone measurements increased in all extension groups receiving teriparatide with optional vibration.

    In plain wordsIn people with spinal cord injury, knee cortical bone increased in all groups during the teriparatide extension with optional vibration.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseKnee cortical bone after extension
    Study

    n = 25

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Those initially randomized to teriparatide also demonstrated 4.4% to 6.7% improvements in hip aBMD after the 12-month extension, while all groups displayed increases in cortical bone measurements at the knee.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 09HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In chronic spinal cord injury, initial teriparatide groups showed hip aBMD improvements after the extension with optional vibration.

    In plain wordsIn people with spinal cord injury, initial teriparatide groups had improved hip bone density after the extension with optional vibration.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseHip aBMD after extension in initial teriparatide groups
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Hip aBMD improvement
    4.4 to 6.7%
    initial teriparatide groups after extension

    Source sentences

    Summary
    Those initially randomized to teriparatide also demonstrated 4.4% to 6.7% improvements in hip aBMD after the 12-month extension, while all groups displayed increases in cortical bone measurements at the knee.
    2 context sentences
    Summary · context
    We randomized 61 individuals with chronic SCI and low bone mass to receive either teriparatide 20 μg/d plus sham vibration 10 min/d (n = 20), placebo plus vibration 10 min/d (n = 20), or teriparatide 20 μg/d plus vibration 10 min/d (n = 21).
    Summary · context
    Patients were evaluated for 12 months; those who completed were given the opportunity to participate in an open-label extension where all participants (n = 25) received teriparatide 20 μg/d for an additional 12 months and had the optional use of vibration (10 min/d).

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.